Novel bioconjugates formed by anti-tumoral drugs, with well-known anti-tumoral activity, and "home-tumour” peptides with proven cellular delivery efficiency and selectivity. These peptides have been validated to be highly specific carriers in leukemic cells but not in healthy limphocytes.